证券代码：300039 证券简称：上海凯宝 公告编号：2026-001 上海凯宝药业股份有限公司 关于使用闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 上海凯宝药业股份有限公司（以下简称"公司"、"上海凯宝"）第六届董事 会第七次会议、2024 年年度股东大会审议通过了《关于使用闲置自有资金进行委托 理财额度的议案》，在保证日常经营运作资金需求、有效控制投资风险的情况下， 同意公司及子公司使用闲置自有资金购买理财产品额度不超过人民币 8 亿元，其年 累计发生额不超过人民币 60 亿元，购买理财产品的额度自股东大会审议通过之日起 12 个月内可滚动使用。同时，在上述额度范围内授权管理层具体实施委托理财事宜， 包括但不限于委托理财的形式、期限及金额等。公司独立董事、监事会均发表了同 意的意见。具体内容详见公司于 2025 年 4 月 16 日、2025 年 5 月 16 日在巨潮资讯 网披露的相关公告。 截至本公告日，公司根据经营情况在以上决议授权范围内，使用闲置自有资金 进行银行理财产品、国债逆回购等委托理财事项，现就具体内 ...

Quantitative Models and Construction Methods 1. Model Name: Large Order Transaction Amount Ratio - **Model Construction Idea**: This model tracks the buying behavior of large funds by calculating the proportion of large order transaction amounts to the total daily transaction amount[7] - **Model Construction Process**: 1. Use tick-by-tick transaction data to identify buy and sell orders based on bid and ask sequence numbers 2. Filter transactions by order size to identify large orders 3. Calculate the ratio of large buy order transaction amounts to the total daily transaction amount - Formula: $ \text{Large Order Transaction Amount Ratio} = \frac{\text{Large Buy Order Transaction Amount}}{\text{Total Daily Transaction Amount}} $ - **Model Evaluation**: This indicator effectively captures the buying behavior of large funds[7] 2. Model Name: Net Active Buy Amount Ratio - **Model Construction Idea**: This model measures the active buying behavior of investors by calculating the net active buy amount as a proportion of the total daily transaction amount[7] - **Model Construction Process**: 1. Use tick-by-tick transaction data to classify each transaction as either active buy or active sell based on the buy/sell flag 2. Calculate the net active buy amount by subtracting the active sell amount from the active buy amount 3. Compute the ratio of the net active buy amount to the total daily transaction amount - Formula: $ \text{Net Active Buy Amount Ratio} = \frac{\text{Active Buy Amount} - \text{Active Sell Amount}}{\text{Total Daily Transaction Amount}} $ - **Model Evaluation**: This indicator effectively captures the active buying behavior of investors[7] --- Model Backtesting Results 1. Large Order Transaction Amount Ratio - **Top 10 Stocks by 5-Day Average**: - **East Securities (601198.SH)**: 88.1%, 99.6% time-series percentile[9] - **Shanghai Kaibao (300039.SZ)**: 86.3%, 100.0% time-series percentile[9] - **Sanxiang Impression (000863.SZ)**: 86.0%, 99.6% time-series percentile[9] - **Chongqing Steel (601005.SH)**: 86.0%, 78.7% time-series percentile[9] - **Jinzhengda (002470.SZ)**: 85.7%, 89.8% time-series percentile[9] - **Wanlong Optoelectronics (300710.SZ)**: 85.6%, 99.6% time-series percentile[9] - **Yasheng Group (600108.SH)**: 85.5%, 84.4% time-series percentile[9] - **Sinochem International (600500.SH)**: 85.5%, 90.4% time-series percentile[9] - **Chongqing Water (601158.SH)**: 85.2%, 96.7% time-series percentile[9] 2. Net Active Buy Amount Ratio - **Top 10 Stocks by 5-Day Average**: - **Jiuhua Tourism (603199.SH)**: 26.2%, 100.0% time-series percentile[10] - **Bailong Oriental (601339.SH)**: 22.9%, 100.0% time-series percentile[10] - **Zijin Bank (601860.SH)**: 20.2%, 100.0% time-series percentile[10] - **Bailong Chuangyuan (605016.SH)**: 19.5%, 100.0% time-series percentile[10] - **Hengshun Vinegar (600305.SH)**: 17.8%, 100.0% time-series percentile[10] - **Qingfangcheng (600790.SH)**: 17.7%, 99.6% time-series percentile[10] - **Shandong Steel (600022.SH)**: 17.7%, 99.6% time-series percentile[10] - **Shengda Forestry (002259.SZ)**: 17.5%, 100.0% time-series percentile[10] - **Taoli Bread (603866.SH)**: 17.2%, 100.0% time-series percentile[10] - **Jiangsu Sopo (600746.SH)**: 16.8%, 100.0% time-series percentile[10] 3. Broad-Based Indices - **5-Day Average Results**: - **Shanghai Composite Index**: Large Order Ratio 73.7% (82.0% percentile), Net Active Buy Ratio 2.2% (3.7% percentile)[12] - **SSE 50**: Large Order Ratio 71.7% (58.2% percentile), Net Active Buy Ratio 5.8% (92.6% percentile)[12] - **CSI 300**: Large Order Ratio 73.0% (41.0% percentile), Net Active Buy Ratio 2.9% (20.9% percentile)[12] - **CSI 500**: Large Order Ratio 73.8% (86.9% percentile), Net Active Buy Ratio 1.5% (3.3% percentile)[12] - **ChiNext Index**: Large Order Ratio 70.5% (6.1% percentile), Net Active Buy Ratio 0.1% (14.8% percentile)[12] 4. Industry-Level Analysis - **Top Industries by 5-Day Average**: - **Steel**: Large Order Ratio 79.0% (79.1% percentile), Net Active Buy Ratio 12.7% (0.8% percentile)[13] - **Agriculture, Forestry, Animal Husbandry, and Fishery**: Large Order Ratio 77.1% (87.7% percentile), Net Active Buy Ratio 10.8% (3.3% percentile)[13] - **Food and Beverage**: Large Order Ratio 71.5% (95.5% percentile), Net Active Buy Ratio 10.1% (32.8% percentile)[13] - **Real Estate**: Large Order Ratio 78.7% (70.9% percentile), Net Active Buy Ratio 8.8% (9.8% percentile)[13] - **Consumer Services**: Large Order Ratio 75.8% (32.4% percentile), Net Active Buy Ratio 8.9% (13.9% percentile)[13] 5. ETF Analysis - **Top 10 ETFs by Large Order Ratio**: - **Haifutong Shanghai Urban Investment Bond ETF (511220.SH)**: 93.4%, 63.5% percentile[15] - **Fortune Military Industry ETF (512710.SH)**: 92.1%, 100.0% percentile[15] - **Guotai CSI A500 ETF (159338.SZ)**: 91.5%, 19.7% percentile[15] - **Guotai 10-Year Treasury ETF (511260.SH)**: 91.5%, 91.8% percentile[15] - **Penghua National Defense ETF (512670.SH)**: 90.7%, 99.6% percentile[15] - **Top 10 ETFs by Net Active Buy Ratio**: - **Huaxia Food and Beverage ETF (515170.SH)**: 18.2%, 99.6% percentile[16] - **Yinhua 5G Communication ETF (159994.SZ)**: 16.7%, 100.0% percentile[16] - **E Fund CSI 300 Non-Bank ETF (512070.SH)**: 16.0%, 95.9% percentile[16] - **Huatai-PineBridge Dividend Low Volatility ETF (512890.SH)**: 15.7%, 94.3% percentile[16] - **Fortune Agriculture ETF (159825.SZ)**: 15.2%, 96.7% percentile[16]

Core Viewpoint - Shanghai Kaibao (300039.SZ) announced that it and its wholly-owned subsidiary, Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical Co., Ltd., have a total of 92 drugs included in the National Medical Insurance Directory, with 50 classified as Category A and 42 as Category B [1] Group 1: Drug Inclusion in National Medical Insurance Directory - The company has three exclusive products (Tanreqing Injection, Tanreqing Capsules, and Qishen Capsules) and one exclusive dosage form (Duo Suo Tea Alkaloid Capsules) continuing in the National Medical Insurance Directory (2025) [1] - The company's products Linggui Zhugan Decoction Granules, Yiguan Decoction Granules, and the subsidiary's Duo Suo Tea Alkaloid Tablets are included in the National Medical Insurance Directory (2025) [1] - The exclusive product Tanreqing Capsules remains in the National Medical Insurance Directory (2025) with a reimbursement standard of 4.09 yuan per (0.4g/piece), valid from January 1, 2026, to December 31, 2027 [1] Group 2: Changes in Drug Status - The subsidiary's products, Compound Robama Tablets and Baldness Pills, have been removed from the National Medical Insurance Directory (2025) [1] - Currently, the removal of the aforementioned products from the insurance directory has no substantial impact on the company's operating performance [1] - Other products' inclusion in the National Medical Insurance Directory (2025) remains unchanged compared to the National Medical Insurance Directory (2024) [1]

Core Viewpoint - Shanghai Kaibao (300039.SZ) announced that it and its wholly-owned subsidiary, Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical Co., Ltd., have a total of 92 drugs included in the National Medical Insurance Directory, with 50 classified as Category A and 42 as Category B [1] Group 1 - The company has three exclusive products (Tan Re Qing injection, Tan Re Qing capsules, and Qi Shen capsules from the subsidiary) and one exclusive dosage form (Duo Suo Tea Alkaloid capsules) that continue to be included in the National Medical Insurance Directory (2025) [1] - The company's products Ling Gui Zhu Gan Tang granules, Yi Guan Jian granules, and the subsidiary's Duo Suo Tea Alkaloid tablets are also listed in the National Medical Insurance Directory (2025) [1] - The exclusive product Tan Re Qing capsules remains in the National Medical Insurance Directory (2025) with a reimbursement standard of 4.09 yuan per (0.4g/piece), with the agreement valid from January 1, 2026, to December 31, 2027 [1] Group 2 - The subsidiary's products, Compound Luo Bu Ma tablets and Ban Hu Wan, have been removed from the National Medical Insurance Directory (2025), but this adjustment has no substantial impact on the company's operating performance [1] - Other products' inclusion in the National Medical Insurance Directory (2025) remains unchanged compared to the National Medical Insurance Directory (2024) [1]

证券代码：300039 证券简称：上海凯宝 公告编号：2025-055 公司子公司产品复方罗布麻片、斑秃丸调出《国家医保目录（2025 年）》，截止 目前上述产品调出医保目录对公司经营业绩无实质影响。 除上述调整外，公司其他产品纳入《国家医保目录（2025 年）》的情况与《国家 医保目录（2024 年）》保持不变。 二、对公司的影响 上海凯宝药业股份有限公司关于公司及子公司 产品在国家医保目录（2025 年）中调整情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 2025 年 12 月 7 日，国家医保局、人力资源社会保障部发布《〈国家基本医疗保险、 生育保险和工伤保险药品目录〉以及〈商业健康保险创新药品目录〉（2025 年）的通 知》（医保发〔2025〕33 号），公布了《国家基本医疗保险、工伤保险和生育保险药 品目录（2025 年）》（以下简称《国家医保目录（2025 年）》）。 上海凯宝药业股份有限公司（以下简称"公司"）及全资子公司上海凯宝新谊（新 乡）药业有限公司（以下简称"子公司"、"新谊药业"）共有 92 个药品纳入国家医 保目录，其中 ...

Core Insights - Shanghai has launched new national-level platforms aimed at enhancing innovation in traditional Chinese medicine and integrated circuit industries [1] Group 1: National Medical Innovation Platform - The National Medical Innovation Platform at Shanghai University of Traditional Chinese Medicine focuses on key technologies such as clinical advantage disease screening and intelligent pharmaceutical development [1] - Five leading companies in the industry, including Shanghai Pharmaceuticals and Shanghai Kaibao Pharmaceutical, have signed agreements to become the first batch of resident units [1] - The "Shanghai University of Traditional Chinese Medicine 7LAB Joint Laboratory" has been officially inaugurated [1] Group 2: Integrated Circuit Innovation Center - The "Integrated Circuit Packaging and Testing Talent Collaborative Innovation Center" is established through collaboration among government, academia, and enterprises [1] - This center aims to create a new high ground for talent integration in the integrated circuit industry [1] - The "Integrated Circuit Packaging and Testing Talent Integration Practice Base" has become a regional demonstration platform for industry-education collaboration, allowing students to engage in real production line environments and complete the entire process from design to testing [1]

Core Insights - The avian influenza concept sector experienced a decline of 0.76%, ranking among the top losers in the market, with major stocks like Zhongsheng Pharmaceutical hitting the limit down, while a few stocks like Wens Foodstuff and Weilan Biology saw gains of 1.80% each [1][2] Market Performance - The top-performing concept sectors included Titanium Dioxide with a gain of 4.31%, and Hainan Free Trade Zone with a gain of 3.54%, while the avian influenza sector was among the worst performers [1] - The avian influenza sector saw a net outflow of 784 million yuan, with 18 stocks experiencing net outflows, led by Zhongsheng Pharmaceutical with a net outflow of 684 million yuan [1] Stock Performance - Stocks with significant net outflows included: - Zhongsheng Pharmaceutical: -10.00% with a turnover rate of 18.78% and a net outflow of 683.65 million yuan - Yiling Pharmaceutical: -2.40% with a net outflow of 35.71 million yuan - Lianhuan Pharmaceutical: -1.79% with a net outflow of 25.69 million yuan - Hualan Biological: -6.60% with a net outflow of 18.13 million yuan [1] - Conversely, stocks with net inflows included: - Tiankang Biological: +1.26% with a net inflow of 16.52 million yuan - Shanghai Kaibao: -1.70% with a net inflow of 5.06 million yuan - Jinhai Biological: +0.16% with a net inflow of 3.82 million yuan [2]

Core Viewpoint - Shanghai Kaibao's stock has shown a mixed performance in recent trading sessions, with a year-to-date increase of 7.57% and a recent decline over the past 60 days [1][2] Group 1: Stock Performance - As of November 26, Shanghai Kaibao's stock price increased by 2.03%, reaching 6.54 CNY per share, with a trading volume of 97.67 million CNY and a turnover rate of 1.64% [1] - The stock has experienced a 3.32% increase over the last five trading days and a 6.00% increase over the last 20 days, while it has decreased by 3.82% over the last 60 days [1] - The company has appeared on the "龙虎榜" (a list of stocks with significant trading activity) once this year, with a net buy of 2.04 million CNY on January 6 [1] Group 2: Financial Performance - For the period from January to September 2025, Shanghai Kaibao reported a revenue of 819 million CNY, a year-on-year decrease of 26.95%, and a net profit attributable to shareholders of 187 million CNY, down 13.83% year-on-year [2] - The company has distributed a total of 1.55 billion CNY in dividends since its A-share listing, with 303 million CNY distributed over the past three years [3] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Shanghai Kaibao was 49,300, a decrease of 6.04% from the previous period, with an average of 18,586 shares held per shareholder, an increase of 6.43% [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 6.99 million shares, an increase of 750,100 shares from the previous period [3]

Dividend Announcements - Jinlu Electronics announced a cash dividend of 0.1483572 CNY per share (tax included), with the record date on November 27, 2025, and the ex-dividend date on November 28, 2025 [1] - Deshi Co. declared a cash dividend of 1.40 CNY for every 10 shares (tax included), with the record date on November 27, 2025, and the ex-dividend date on November 28, 2025 [1] - Shanghai Kaibao will distribute a cash dividend of 0.30 CNY for every 10 shares (tax included), with the record date on November 26, 2025, and the ex-dividend date on November 27, 2025 [1] Additional Dividend Announcements - Shichang Co. announced a cash dividend of 5.80 CNY for every 10 shares (tax included), with the record date on November 27, 2025, and the ex-dividend date on November 28, 2025 [2] - Mylande declared a cash dividend of 0.30 CNY per share (tax included), with the record date on November 26, 2025, and the ex-dividend date on November 27, 2025 [2] - Zhiyang Innovation announced a cash dividend of 0.10 CNY per share (tax included), with the record date on November 26, 2025, and the ex-dividend date on November 27, 2025 [2] Further Dividend Announcements - Shentong Technology declared a cash dividend of 0.027 CNY per share (tax included), with the record date on November 26, 2025, and the ex-dividend date on November 27, 2025 [3] - Jinshi Resources announced a cash dividend of 0.07 CNY per share (tax included), with the record date on November 27, 2025, and the ex-dividend date on November 28, 2025 [3] - Gibit declared a cash dividend of 6.00 CNY per share (tax included), with the record date on November 27, 2025, and the ex-dividend date on November 28, 2025 [3] Final Dividend Announcements - Puris announced a cash dividend of 0.68 CNY for every 10 shares (tax included), with the record date on November 27, 2025, and the ex-dividend date on November 28, 2025 [4] - Kaipu Testing declared a cash dividend of 2.00 CNY for every 10 shares (tax included), with the record date on November 27, 2025, and the ex-dividend date on November 28, 2025 [4]

Core Viewpoint - Shanghai Kaibao announced a profit distribution plan for the first three quarters of 2025, proposing a cash dividend of 0.3 RMB per 10 shares to all shareholders, including tax [1] Summary by Relevant Sections - **Profit Distribution Plan** - The company will distribute a cash dividend of 0.3 RMB per 10 shares to shareholders [1] - The record date for the dividend is set for November 26, 2025, and the ex-dividend date is November 27, 2025 [1]